Gaseous and air decontamination technologies for Clostridium difficile in the healthcare environment
Gaseous and air decontamination technologies for Clostridium difficile in the healthcare environment
复制标题
DOI：
10.1016/j.jhin.2010.08.012
复制
发表时间：
2011-03-01
影响因子：
6.9
通讯作者：
Walker, J.
中科院分区：
文献类型：
--
作者：
Davies, A.;Pottage, T.;Walker, J.
最近的医院获得性感染数据表明，耐甲氧西林金黄色葡萄球菌（MRSA）和艰难梭菌的感染率开始下降。然而，尽管维持这一趋势仍有压力，但C。艰难梭菌孢子与标准洗涤剂的接触仍然是许多英国医院试图防止其传播或控制疫情的一个问题。替代消毒技术（如气体净化）目前正在向医疗保健部门销售，作为手动消毒的替代/补充，并已被证明可有效减少环境污染。如果使用正确，它们可以提供手动清洁的补充技术，增加有效降低活力的可能性，并提供相对均匀的消毒剂分布。本文对三种气体净化技术进行了研究，以确定它们在减少C. difficile：气态过氧化氢，二氧化氯和臭氧。还简要介绍了空气净化和紫外线技术。我们的结论是，虽然有一个角色，发挥这些新技术在净化病房表面污染的C。然而，由于在使用前需要进行预清洁以及有限的“体内”证据，因此需要进行广泛的现场试验以确定其在医疗保健环境中的成本效益。(C)2010年，医院感染协会。由爱思唯尔有限公司出版。保留所有权利。
The recent data for hospital-acquired infections suggest that infection rates for meticillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile are beginning to decrease. However, while there is still pressure to maintain this trend, the resistance of C. difficile spores to standard detergents continues to present a problem for many UK hospitals trying to prevent its spread or control outbreaks. Alternative disinfection technologies such as gaseous decontamination are currently being marketed to the healthcare sector as an alternative/supplement to manual disinfection, and have been shown to be effective in reducing environmental contamination. When used correctly, they offer a complementary technology to manual cleaning that increases the probability of an effective reduction in viability and provides a comparatively uniform distribution of disinfectant. Three gaseous decontamination technologies are examined for their suitability in reducing environmental contamination with C. difficile: gaseous hydrogen peroxide, chlorine dioxide and ozone. Air decontamination and UV-based technologies are also briefly described. We conclude that while there is a role to play for these new technologies in the decontamination of ward surfaces contaminated with C. difficile, the requirement for both a preclean before use and the limited 'in vivo' evidence means that extensive field trials are necessary to determine their cost-effectiveness in a healthcare setting. (C) 2010 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.